Prior preterm or small-for-gestational-age birth related to XXXX .

@entity1 @entity2298 @entity101 @entity6 @entity1674 @entity600 @entity413 @entity1468 @entity209 @entity65 @entity165
OBJECTIVE: To estimate whether @entity1 who deliver small babies due to @entity600 or growth restriction have excess risk for @entity65 and @entity6 later in life. METHODS: Eight years after pregnancy, we estimated the prevalence of @entity209 and its components in a cohort study of @entity1 with prior preterm ( @entity600 before 37 weeks, n=181) or small for gestational age ([SGA], less than the tenth percentile, n=192) births, compared with @entity1 with term births (37 or more weeks, n=306). @entity1 delivered at Magee-Womens Hospital in Pittsburgh, Pennsylvania, and those with @entity1468 or prepregnancy @entity6 or @entity101 were excluded. @entity1 underwent a structured interview and fasting blood sampling. RESULTS: @entity1 were, on average, 8 years postpartum and 39 years old at evaluation. @entity1 with a prior @entity600 had higher blood pressure, @entity1674 , and LDL- @entity165 compared with those in a term control group. @entity1 with prior SGA births were leaner and more likely to smoke compared with those with term births. @entity1 with prior @entity600 had elevated risk of @entity209 , adjusted for demographic, smoking and body size factors (23% preterm compared with 17% control group; odds ratio [OR] 1.76 [1.06, 2.80]). In @entity1 with a prior @entity600 , low HDL (11% preterm compared with 5% control group; OR 2.6 [1.2, 5.2]), @entity2298 (22% compared with 14%; OR 1.9 [1.2, 2.9]), and elevated @entity413 (24% compared with 19%; OR 1.5 [1.0, 2.3]) accounted for this excess @entity209 . In @entity1 with SGA, the only element of @entity209 that was aberrant was @entity413 metabolism. CONCLUSION: Eight years after pregnancy, @entity1 with prior preterm or SGA births had evidence of @entity209 compared with @entity1 with term births. Screening and intervention in these @entity1 after pregnancy may delay or prevent disease. LEVEL OF EVIDENCE: : II.
